VENTINOVA MEDICAL BV

Their core work

Ventinova Medical is a Dutch medical device SME developing advanced mechanical ventilation technology for intensive care patients. Their work centers on reducing ventilator-induced lung injury (VILI) — a serious complication where the very machines keeping critically ill patients alive cause additional lung damage. They design harmless respiration systems aimed at lowering ICU mortality, shortening hospital stays, and improving outcomes for patients with acute respiratory distress syndrome (ARDS), including those hit by COVID-19. Based in Eindhoven's medtech ecosystem, they take their own technology from development through clinical validation and market deployment.

What they specialise in

How they've shifted over time

In their first H2020 project (EVA, 2015-2018), Ventinova worked on patient ventilation technology with a broad framing — pushing beyond the limits of existing devices. By the second project (Jane, 2020-2022), their focus sharpened dramatically toward a specific clinical problem: preventing ventilator-induced lung injury in ARDS and COVID-19 patients. The jump in EC funding (from EUR 793K to EUR 2.5M) and the pandemic-era timing suggest their core technology found strong clinical relevance exactly when the world needed better ventilation solutions.

Moving from general ventilation innovation toward clinically validated, economically justified solutions for severe respiratory failure — a strong position for partners in critical care medtech.

How they like to work

Ventinova leads its own projects — both H2020 grants were coordinator roles, with small consortia (only 4 unique partners total across both projects). This is characteristic of a product-focused SME using EU funding to advance its own technology rather than acting as a service partner in someone else's agenda. Expect them to drive timelines and own the core IP, while seeking clinical, manufacturing, or validation partners around them.

A small, focused network: 4 unique partners across 4 countries over two projects. The footprint is European rather than global, consistent with an SME using H2020 to bring a device to clinical and commercial readiness.

What sets them apart

Ventinova is one of very few H2020-funded SMEs tackling the specific problem of ventilator-induced lung injury — a known but under-addressed cause of ICU mortality. Unlike large medical device firms that sell general-purpose ventilators, they are building purpose-designed technology for the most damaged lungs. For a partner, this means access to a focused technology owner who has already navigated two SME-track EU grants and can move from device concept toward clinical evidence.

Highlights from their portfolio

• Jane
  Their largest project (EUR 2.5M), launched in 2020 with direct COVID-19 relevance and explicit targeting of VILI in ARDS patients.
• EVA
  Earlier SME-2 project that established their position in ICU ventilation technology and set up the clinical focus they later deepened.